Gotowa bibliografia na temat „Active approximately 610-approximately 580 b”

Objectives In order to generate independent performance data regarding accuracy of COVID-19 antigen-based rapid diagnostic tests (Ag-RDTs), prospective diagnostic evaluation studies across multiple sites are required to evaluate their performance in different clinical settings. This report describes the clinical evaluation the GENEDIA W COVID-19 Ag Device (Green Cross Medical Science Corp., Chungbuk, Korea) and the ActiveXpress+ COVID-19 Complete Testing Kit (Edinburgh Genetics Ltd, UK), in two testing sites Peru and the United Kingdom. Methods Nasopharyngeal swabs collected from 456 symptomatic patients at primary points of care in Lima, Peru and 610 symptomatic participants at a COVID-19 Drive-Through testing site in Liverpool, England were analyzed by Ag-RDT and compared to RT-PCR. Analytical evaluation of both Ag-RDTs was assessed using serial dilutions of direct culture supernatant of a clinical SARS-CoV-2 isolate from the B.1.1.7 lineage. Results For GENEDIA brand, the values of overall sensitivity and specificity were 60.4% [95% CI 52.4–67.9%], and 99.2% [95% CI 97.6–99.7%] respectively; and for Active Xpress+ the overall values of sensitivity and specificity were 66.2% [95% CI 54.0–76.5%], and 99.6% [95% CI 97.9–99.9%] respectively. The analytical limit of detection was determined at 5.0 x 102 pfu/ml what equals to approximately 1.0 x 104 gcn/ml for both Ag-RDTs. The UK cohort had lower median Ct values compared to that of Peru during both evaluations. When split by Ct, both Ag-RDTs had optimum sensitivities at Ct<20 (in Peru; 95% [95% CI 76.4–99.1%] and 100.0% [95% CI 74.1–100.0%] and in the UK; 59.2% [95% CI 44.2–73.0%] and 100.0% [95% CI 15.8–100.0%], for the GENDIA and the ActiveXpress+, respectively). Conclusions Whilst the overall clinical sensitivity of the Genedia did not meet WHO minimum performance requirements for rapid immunoassays in either cohort, the ActiveXpress+ did so for the small UK cohort. This study illustrates comparative performance of Ag-RDTs across two global settings and considers the different approaches in evaluation methods.

570 patients with acute ankle joint distortion were randomized to four treatment groups: a combination spray of arnica tincture and hydroxyethyl salicylate (HES; group A, ), arnica (B, ), HES (C, ), and placebo (D, ). The medication was applied 4-5 times daily for 10 days. Efficacy was assessed on day 3-4 by evaluating pain on motion on a visual analogue scale (VAS). Pain improvement in group A was significantly superior over groups B–D (-test with unadjusted baseline values, and ANCOVA after adjustment, ) and approximately corresponded to the cumulative effect of the single constituents (12.1, 7.5, and 18.7 mm VAS for A versus B, A versus C, and A versus D; 95% CI 8.0–16.2, 4.7–10.4, and 14.8–22.5 mm). The combination is justified by the additive effects of the single active constituents.

Corrosion fatigue crack propagation tests were conducted on a high-sulfur ASTM A302-B plate steel overlaid with weld-deposited Alloy EN82H cladding. The specimens featured semi-elliptical surface cracks penetrating approximately 6.3 mm of cladding into the underlying steel. The initial crack sizes were relatively large with surface lengths of 22.8–27.3 mm, and depths of 10.5–14.1 mm. The experiments were initiated in a quasi-stagnant low-oxygen (O2 < 10 pph) aqueous environment at 243°C, under loading conditions (ΔK, R, cyclic frequency) conducive to environmentally assisted cracking (EAC) under quasi-stagnant conditions. Following fatigue testing under quasi-stagnant conditions where EAC was observed, the specimens were then fatigue tested under conditions where active water flow of either 1.7 m/s or 4.7 m/s was applied parallel to the crack. Earlier experiments on unclad surface-cracked specimens of the same steel exhibited EAC under quasi-stagnant conditions, but water flow rates at 1.7 m/s and 5.0 m/s parallel to the crack mitigated EAC. In the present experiments on clad specimens, water flow at approximately the same as the lower of these velocities did not mitigate EAC, and a free stream velocity approximately the same as the higher of these velocities resulted in sluggish mitigation of EAC. The lack of robust EAC mitigation was attributed to the greater crack surface roughness in the cladding interfering with flow induced within the crack cavity. An analysis employing the computational fluid dynamics code, FIDAP, confirmed that frictional forces associated with the cladding crack surface roughness reduced the interaction between the free stream and the crack cavity.

Nuclear organization and chromatin interactions are important for genome function, yet determining chromatin connections at high resolution remains a major challenge. To address this, we developed Accessible Region Conformation Capture (ARC-C), which profiles interactions between regulatory elements genome-wide without a capture step. Applied to Caenorhabditis elegans, ARC-C identifies approximately 15,000 significant interactions between regulatory elements at 500-bp resolution. Of 105 TFs or chromatin regulators tested, we find that the binding sites of 60 are enriched for interacting with each other, making them candidates for mediating interactions. These include cohesin and condensin II. Applying ARC-C to a mutant of transcription factor BLMP-1 detected changes in interactions between its targets. ARC-C simultaneously profiles domain-level architecture, and we observe that C. elegans chromatin domains defined by either active or repressive modifications form topologically associating domains (TADs) that interact with A/B (active/inactive) compartment-like structure. Furthermore, we discover that inactive compartment interactions are dependent on H3K9 methylation. ARC-C is a powerful new tool to interrogate genome architecture and regulatory interactions at high resolution.

Boophone disticha (B. disticha) has been used systemically in traditional medical practice in Zimbabwe and neighbouring countries for the management of various central nervous system conditions including hysteria. Abuse of the plant by teenagers in Zimbabwe for its claimed hallucinogenic effects has also been reported, with the advent of serious toxicity in some cases. In the present work, we describe the acute toxicity and neurotoxicological effects of a freeze dried hydro-ethanolic plant extract of the bulb of B. disticha. Thirty-three adult (6—12 weeks old), non-pregnant female Sprague Dawley rats were used for the oral LD50 estimation. Animals were given doses of 50, 120, 240, 360, 500 and 700 mg/kg and were observed using a modified Functional Observation Battery (FOB) for behavioural toxicity. The estimated oral LD50 of the plant extract was between 120 and 240 mg/kg. For doses of 240 mg/kg and less, signs of toxicity began approximately 10 minutes after gavage, and the most prominent initial signs were head tremors (at 50 mg/kg) and body tremors, severe body tremors(>360 mg/kg) followed by convulsions. Generally, symptoms of toxicity lasted approximately 2 hours for doses of 240 mg/kg and less; and 3 hours for doses over 240 mg/kg for animals that survived. These results point to a rapid gastrointestinal absorption of the active principles in the plant extract. The most prominent neurotoxicological effects were increased flaccid limb paralysis and spastic hind-limb paralysis. Tachypnoea was noted at low doses and higher doses produced laboured breathing. The retropulsion observed with higher doses could indicate the reported hallucinogenic effects of the plant extract.

TPS7592 Background: Consensus treatment guidelines are unavailable for patients with diffuse large B-cell lymphoma (DLBCL) whose disease progresses after first-line therapy. The receptor tyrosine kinase-like orphan receptor 1 (ROR1) is a transmembrane protein that is overexpressed in multiple cancers, including hematological malignancies. Zilovertamab vedotin (ZV; MK-2140, previously known as VLS-101), an antibody-drug conjugate comprising a humanized IgG1 monoclonal antibody, a proteolytically cleavable linker, and the antimicrotubule cytotoxic agent monomethyl auristatin E, targets ROR1 and has shown promising efficacy and tolerability in hematological malignancies, including DLBCL. This 2-part (part 1, dose confirmation; part 2, dose expansion), open-label, randomized, active-control, phase 2/3 study (NCT05139017) will assess safety and efficacy of ZV + standard of care in patients with relapsed/refractory (R/R) DLBCL. Methods: Eligible adult patients must have histologically confirmed DLBCL per WHO classification, ineligible for or have failed autologous stem cell transplantation and chimeric antigen receptor T cell therapy, R/R DLBCL after ≥1 line of prior therapy (cohort A) or ≥2 lines of prior therapy (cohort B), measurable disease per Lugano 2014 criteria, and Eastern Cooperative Oncology Group performance status ≤2. Approximately 420 patients will be enrolled in the study (cohort A, n = 230; cohort B, n = 190). In the part 1 dose confirmation phase, 30 patients from cohort A will receive ZV (at increasing doses: 1.5, 1.75, 2.0, 2.25, and 2.5 mg/kg; starting at 1.75 mg/kg) plus gemcitabine-oxaliplatin + rituximab (R-GemOx) to establish the recommended phase 2 dose using the mTPI design. A safety run-in phase of part 2 will include 30 patients from cohort B and will receive ZV + bendamustine and rituximab (BR). Approximately 360 patients will be included in the part 2 dose expansion phase (cohort A, n = 200; cohort B, n = 160). Patients from cohort A will be randomly assigned 1:1 to 6 cycles of either ZV + R-GemOx or R-GemOx. Patients from cohort B will be randomly assigned 1:1 to 6 cycles of either ZV + BR or BR. Disease response assessments by CT and PET scans will occur every 12 weeks until disease progression or study discontinuation. Adverse events (AEs) will be monitored throughout the study and graded per NCI CTCAE version 5.0. In part 1, the primary end point is safety, including DLTs, AEs, and discontinuation due to AEs. The primary end point for cohorts A and B in the dose expansion phase of part 2 will be progression-free survival by blinded independent central review per Lugano 2014 criteria. Key secondary end points in the dose expansion phase of part 2 for both cohorts include objective response rate (including complete response and partial response) and duration of response, both per Lugano 2014 criteria and overall survival. Clinical trial information: NCT05139017.

Gallium maltolate, tris(3-hydroxy-2-methyl-4H-pyran-4-onato)gallium (GaM), is an orally active gallium compound for therapeutic use. It is moderately soluble in water (10.7 ± 0.9 mg/mL at 25C∘) with an octanol partition coefficient of 0.41±0.08. The molecule is electrically neutral in aqueous solution at neutral pH; a dilute aqueous solution (2.5 ×10−5 M) showed little dissociation at pH 5.5-8.0. Single crystal X-ray diffraction analysis found the GaM molecule to consist of three maltolate ligands bidentately bound to a central gallium atom in a propeller-like arrangement, with one of the ligands disordered in two possible orientations. The compound is orthorhombic, space group Pbca, unit cell a = 16.675(3), b = 12.034(2), c = 18.435(2) A∘ at 158K. GaM was administered to healthy human volunteers at single doses of 100, 200, 300, and 500 mg (three subjects per dose). GaM was very well tolerated. Oral absorption of Ga into plasma was fairly rapid (absorption half life = 0.8-2.0h), with a central compartment excretion half life of 17-21h. Absorption appeared dose proportional over the dosage range studied. Estimated oral gallium bioavailability was approximately 25-57%, based on comparison with published data on intravenous gallium nitrate. Urinary Ga excretion following oral GaM administration was approximately 2% of the administered dose over 72h, in contrast to 49-94% urinary Ga excretion over 24h following i.v. gallium nitrate administration. We suggest that oral administration of GaM results in nearly all plasma gallium being bound to transferrin, whereas i.v. administration of gallium nitrate results in formation of considerable plasma gallate [Ga(OH)4−], which is rapidly excreted in the urine. These data support the continued investigation of GaM as an orally active therapeutic gallium compound.

During characterization of the surface antigens of serotype III group B streptococci (GBS), a protein with an apparent Mr~ 173 500 migrating on a SDS – polyacrylamide gel was found to have an N-terminal amino acid sequence identical to that of the plasmin receptor (Plr) of group A streptococci, a surface-localized glyceraldehyde-3-phosphate dehydrogenase (GAPDH). This work begins to characterize GBS GAPDH and to assess its functional activity on the cell surface. The 1.0-kb gapC gene of GBS was amplified by PCR. plr and gapC demonstrated 87% homology. An anti-Plr monoclonal antibody reacted with GBS whole cells, suggesting GBS GAPDH is surface localized. Multiple serotypes of GBS demonstrated functional GAPDH on their surfaces. The anti-Plr monoclonal antibody recognized GBS protein bands of approximately 41 and 173.5 kDa, by Western blot. Presumably, these represent monomeric and tetrameric forms of the GAPDH molecule. GBS GAPDH was demonstrated by Western blot analysis to interact with lys- and glu-plasminogens. Fluid-phase GBS GAPDH interacted, by means of ELISA, with immobilized lys-plasminogen, glu-plasminogen, actin, and fibrinogen. Enzymatically active GAPDH, capable of binding cytoskeletal and extracellular matrix proteins, is expressed on the surface of GBS.Key words: group B streptococci, glyceraldehyde-3-phosphate dehydrogenase.

The use of bacterial probiotic metabolite-based active-packaging and coatings is an innovative approach that has gained widespread attention worldwide. Additionally, its utilization can lead to improvements in qualities and properties of food products. This study was aimed to develop a food spoilage prevention system using active food packaging and coating material in preventing food spoilage while increasing its shelflife. The materials used were bacterial cellulose (BC) based bioplastics fortified with fermented soymilk extracts (FSME) using Lactobacillus acidophilus as the producer of the antimicrobial and antioxidant agents. Moreover, the applications of FSME containing probiotic bacterial metabolites are discussed to highlight their efficacy in enhancing the quality and shelf life of food products.The antimicrobial test showed that the FSME could inhibit the growth of pathogenic microbial cultures at minimum inhibitory concentration (MIC) of 10% (v/v) as shown by clear zones, around colonies of E. coli (14.33±0.58 mm), S. aureus (18.33±6.03 mm), S. Typhimurium (11.67±1.15 mm), L. monocytogenes (11.33±2.31 mm), and B. cereus (13.33±3.06 mm). Meanwhile the results of IC50 for antioxidant activity test (µg/mL) indicated that the FSME showed radical scavenging activity against DPPH at approximately 75.27±2.552 (2.5%, v/v), 55.00±0.791 (5.0%, v/v), 43.17±1.603 (7.5%, v/v) and 15.05±0.346 (10%, v/v), respectively. The shelflife of strawberries coated with the active food coating using the bioplastic fortified with FSME showed an increase in shelf life of 14 days at 4°C. The overall results indicated that the use of BC based bioplastics fortified with FSME can play an important role in preventing premature spoilage and increasing the shelf life of food products.

Abstract The effects of bacterial direct-fed microbial (DFM) mixtures on beef cattle feeding behavior were evaluated. Six ruminally cannulated crossbred Angus steers (BW = 520 ± 30 kg) were used in a replicated 3 × 3 Latin Square design. Steers were offered a steam-flaked corn-based finishing diet to ad libitum during three, 28 d periods (21-d adaptation and 7-d collection). Treatments assigned were: 1) Control (no DFM, lactose carrier only); 2) Treat-A [L. animalis, P. freudenreichii; B. subtilis; and B. licheniformis, at 1:1:1:3 ratio, respectively; totaling 6 × 109 CFU (50mg)/animal-daily minimum (Chr.Hansen]; and 3) Treat-B, the same DFM combination, but with doses at 1:1:3:1 ratio. Bacterial counts were approximately 30% greater than the minimum expected. The DFM diluted mixtures and carrier (Control) were pre-weighed and stored at -20°C until incorporated into the diet (2 g· animal-1· /day-1) 10 min prior to feeding. For mixing, approximately 1 kg (as is) of the diet being offered was removed from the individual recipient, DFM was mixed by hand, and the mixture was incorporated into the feed allocated for the day. The feeding behavior assessment consisted of a 24 h continuous visual observation (every 5 min) performed by trained personnel. Animals were assessed on d 26 of each period (no other management other than cleaning of the stall), while time spent eating, ruminating, resting, active, and drinking were taken. Time spent chewing was accounted for by adding time spent eating and ruminating. In addition, records allowed the count of the number of meals taken, as well as the time spent on each meal. Data were analyzed using the GLIMMIX procedure of SAS, with animal considered as the experimental unit, the fixed effects of treatment, and random effect of square, period, and animal (square). F-test protected pre-planned orthogonal contrasts was used to compare Control vs. Treat-A and Control vs. Treat-B. Meal number (16/d) and length (8 min/meal) were not affected by treatments (P ≥ 0.54). Main feeding behavior variables consisting of rumination (198 min/d), eating (117 min/d), chewing (315 min/d), drinking (22 min/d), resting (929 min/d), and active (174 min/d) were not affected (P ≥ 0.24) by treatments. A tendency was observed (P = 0.08) where animals offered the Treat-B spent numerically less time ruminating per unit of digestible DM and OM intake compared with Control (13.5 vs. 15.5, and 13.7 vs 15.6 min/kg, respectively). Other behaviors measured in min/kg of DM, NDF, and ADF intake were not affected (P ≥ 0.17) by treatments [rumination (11.5, 60.2, and 181), eating (6.5, 34.4, and 104), chewing (18, 94.6, and 285), and drinking (1.2, 6.6, and 19.8) min/kg, respectively]. The bacterial DFM mixtures offered appear not to directly affect the feeding behavior of beef cattle consuming a steam-flaked corn-based finishing diet.

The Browns Hole quadrangle is in Weber and Cache Counties of northern Utah and covers the eastern part of Ogden Valley, a rapidly developing area of the Wasatch Range. The Middle and South Forks of the Ogden River bisect the quadrangle and are important watersheds and recreational areas to the communities of Ogden Valley and the Wasatch Front. The towns of Huntsville and Eden are just west of the quadrangle, unincorporated communities with year-round residents are present throughout the quadrangle, and numerous summer-cabin communities are present in the eastern part of the quadrangle. A portion of Powder Mountain ski resort, which draws year-round visitation and recreation, is present in the northwest corner of the quadrangle. The quadrangle contains the Willard thrust, a major thrust fault with approximately 30 mi (50 km) of eastward displacement that was active during the Cretaceous-Eocene Sevier orogeny (Yonkee and others, 2019). In the quadrangle, the Willard thrust places Neoproterozoic through Ordovician strata in the hanging wall over a fault-bounded lozenge of Cambrian strata and footwall Jurassic and Triassic strata (see cross section on Plate 2). Neoproterozoic strata comprise a succession of mostly clastic rocks deposited during rifting of western North America and breakup of the supercontinent Rodinia (Yonkee and others, 2014). These rocks include the Cryogenian-age Perry Canyon and Maple Canyon Formations, and the Ediacaran-age Kelley Canyon Formation, Papoose Creek Formation, Caddy Canyon Quartzite, Inkom Formation, Mutual Formation, and Browns Hole Formation. The Browns Hole Formation is a sequence of interbedded volcaniclastic rock and basalt lava flows that provides the only radiometric age control in the quadrangle. Provow and others (2021) reported a ~610 Ma detrital apatite U-Pb age from volcaniclastic sandstone at the base of the formation, Crittenden and Wallace (1973) reported a 580 ± 14 Ma K-Ar hornblende age for a volcanic clast, and Verdel (2009) reported a 609 ± 25 Ma U-Pb apatite age for a basalt flow near the top of the formation. Cambrian strata in the hanging wall include a thick basal clastic sequence (Geertsen Canyon Quartzite) overlain by a thick sequence of interbedded limestone, shale, and dolomite (Langston, Ute, and Blacksmith Formations). Hanging wall rocks are deformed by Willard thrust-related structures, including the Browns Hole anticline, Maple Canyon thrust, and numerous smaller folds and minor faults. Footwall rocks of the Willard thrust include highly deformed Cambrian strata within a fault-bounded lozenge exposed in the southern part of the quadrangle, and Jurassic and Triassic rocks exposed just south of the quadrangle. The Paleocene-Eocene Wasatch Formation unconformably overlies older rocks and was deposited over considerable paleotopography developed during late stages of the Sevier orogeny. The southwest part of the quadrangle is cut by a southwest-dipping normal fault system that bounds the east side of Ogden Valley. This fault is interpreted to have experienced an early phase of slip during local late Eocene to Oligocene collapse of the Sevier belt and deposition of volcanic and volcaniclastic rocks (Norwood Tuff) exposed west of the quadrangle (Sorensen and Crittenden, 1979), and a younger phase of slip during Neogene Basin and Range extension (Zoback, 1983). Lacustrine deposits and shorelines of Pleistocene-age Lake Bonneville are present in the southwest corner of the quadrangle near the mouth of the South Fork of the Ogden River and record the highstand of Lake Bonneville (Oviatt, 2015). Pleistocene glacial deposits, present in the northwest corner of the map, are likely related to the Pinedale glaciation, commonly expressed by two moraine building episodes in the Wasatch Range (Quirk and others, 2020). Numerous incised alluvial deposits and geomorphic surfaces are present along major drainages and record pre- and post-Lake Bonneville aggradational and degradational alluvial and colluvial sequences. Mass-movement deposits, including historically active landslides, are present throughout the quadrangle. Crittenden (1972) mapped the Browns Hole quadrangle at 1:24,000 scale, which provided an excellent foundation for the general stratigraphy and structure, but the 1972 map lacked important details of unconsolidated surficial units. As part of 1:62,500 scale mapping of the Ogden 30'x60' quadrangle, Coogan and King (2016) updated stratigraphic nomenclature, revised some contacts, and added more details for surficial units. For this map, we utilized new techniques for data acquisition and analysis to delineate surficial deposits, bedrock contacts, and faults more accurately and precisely. Mapping and field data collection were largely done in 2021–2022 using a combination of GPS-enabled tablets equipped with georectified aerial imagery (U.S. Department of Agriculture [USDA] National Agriculture Imagery Program [NAIP], 2009), orthoimagery (Utah Geospatial Resource Center [UGRC] State Geographic Information Database, 2018b, 2018c; 2021a, 2021b), and lidar data (UGRC State Geographic Information Database, 2006; 2011; 2013–2014; 2018a), previously published geologic maps, topographic maps, and applications for digital attitude collection. We also used hand-held GPS units, Brunton compasses, and field notebooks to collect geologic data. Field data were transferred to a Geographic Information System (GIS), where the map was compiled and completed.